Pipeline
We are advancing best-in-class CD8 Treg modulators designed to restore healthy immune system function to effectively treat and potentially cure autoimmune diseases.
Pipeline
CeD: celiac disease; T1D: type 1 diabetes mellitus; IBD: inflammatory bowel disease
Learn more about our programs
MTX-101 (KIR x CD8)
MTX-101 is a bispecific autoimmune checkpoint inhibitor. Its dual configuration binds the CD8 Treg receptors, KIR and CD8, to selectively activate CD8 Treg and enhance MTX-101’s specificity, respectively. MTX-101 is designed to restore CD8 Treg functionality and the destruction of pathogenic immune cells.
A Phase 1 study of MTX-101 in healthy adults is complete (NCT06324604). Results show that MTX-101 is generally safe and well-tolerated and selectively activates CD8 Treg. The second part of this study to evaluate MTX-101 in patients with type 1 diabetes and celiac disease is currently ongoing.
MTX-201 (KIR x ICOS)
MTX-201 is a bispecific antibody that restores and potentiates the functionality of CD8 Treg via inhibition of KIR and activation of the ICOS costimulatory receptor, respectively, both expressed on CD8 Treg.
It is being developed for the treatment of highly inflammatory autoimmune diseases, such as inflammatory bowel diseases (IBD; a term used to encompass two chronic and often life-threatening diseases of the gastrointestinal tract: Crohn’s disease and ulcerative colitis).
